ArticleFrontiers in pharmacology2025

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA's adverse event reporting system database.

Qun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.